Bausch Health Companies Inc. Stock
$5.42
2.26%
NYSE,
May 02, 10:10 pm CET
Bausch Health Companies Inc. Stock price
$5.42
-0.69
11.29%
1M
-3.84
41.47%
6M
-2.64
32.75%
YTD
-2.67
33.00%
1Y
-13.43
71.25%
3Y
-11.26
67.51%
5Y
-217.44
97.57%
10Y
NYSE,
Closing price Fri, May 02 2025
+0.12
2.26%
Powered by
ISIN
CA0717341071
Symbol
BHC
Index
Sector
Industry
Key metrics
| Market capitalization | $2.00b |
| Enterprise Value | $23.30b |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | 19.49 |
| EV/Sales (TTM) EV/Sales | 2.39 |
| P/S ratio (TTM) P/S ratio | 0.21 |
| P/B ratio (TTM) P/B ratio | negative |
| Revenue growth (TTM) Revenue growth | 8.53% |
| Revenue (TTM) Revenue | $9.73b |
Show more
Is Bausch Health Companies Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,785 stocks worldwide.
Bausch Health Companies Inc. Stock Analysis
Unlock Scores for Free
Analyst Opinions
6 Analysts have issued a Bausch Health Companies Inc. forecast:
Analyst Opinions
6 Analysts have issued a Bausch Health Companies Inc. forecast:
Hold
83%
Sell
17%
Financial data from Bausch Health Companies Inc.
| Mar '25 |
+/-
%
|
||
| Revenue | 9,731 9,731 |
9%
9%
|
|
| Gross Profit | 5,829 5,829 |
11%
11%
|
|
| EBITDA | 3,104 3,104 |
6%
6%
|
EBIT (Operating Income) EBIT | 1,852 1,852 |
11%
11%
|
| Net Profit | -40 -40 |
91%
91%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Bausch Health Companies Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Bausch Health Companies Inc. Stock News
Neutral
Seeking Alpha
●
4 days ago
Bausch Health Companies Inc. (NYSE:BHC ) Q1 2025 Earnings Conference Call April 30, 2025 5:00 PM ET Company Participants Garen Sarafian - IR Thomas Appio - CEO Jean-Jacques Charhon - EVP & CFO Conference Call Participants Les Sulewski - Truist Securities Doug Miehm - RBC Capital Michael Nedelcovych - TD Cowen Jason Gerberry - Bank of America Michael Freeman - Raymond James Operator Greetings. W...
Neutral
Accesswire
●
5 days ago
First Quarter Consolidated Revenues of $2.26 billion, up 5% on a Reported basis and 6% on an Organic (non-GAAP) 1 basis over the prior year period GAAP Net Loss Attributable to Bausch Health Companies of $58 million and GAAP Net Loss of $86 million Consolidated Adjusted EBITDA Attributable to Bausch Health Companies (non-GAAP) 1 of $661 million, in line with prior year period BAUSCH HEALTH EXCL...
Neutral
Accesswire
●
6 days ago
A Long-Awaited Advancement in Non-Invasive Radiofrequency Skin Tightening Is Now Approved for the Canadian Market LAVAL, QC / ACCESS Newswire / April 29, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its aesthetic business, Solta Medical, announced today that Health Canada has granted medical device license clearance for Thermage® FLX...
Company Profile
Manufactures and markets pharmaceutical products
| Head office | Canada |
| CEO | Thomas Appio |
| Employees | 20,700 |
| Founded | 1994 |
| Website | www.bauschhealth.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
